Full Text:   <3568>

CLC number: R73

On-line Access: 2010-01-01

Received: 2009-06-12

Revision Accepted: 2009-10-13

Crosschecked: 2009-12-02

Cited: 2

Clicked: 5462

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2010 Vol.11 No.1 P.22-26


Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern

Author(s):  Bo ZHANG, Qiu-ping XIE, Shun-liang GAO, Yan-biao FU, Yu-lian WU

Affiliation(s):  Department of Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   wuyulian@medmail.com.cn

Key Words:  Neuroendocrine tumor, Somatostatinoma, Somatostatinoma syndrome, Pancreatic hormone-producing tumor, Pancreatectomy

Bo ZHANG, Qiu-ping XIE, Shun-liang GAO, Yan-biao FU, Yu-lian WU. Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern[J]. Journal of Zhejiang University Science B, 2010, 11(1): 22-26.

@article{title="Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern",
author="Bo ZHANG, Qiu-ping XIE, Shun-liang GAO, Yan-biao FU, Yu-lian WU",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern
%A Qiu-ping XIE
%A Shun-liang GAO
%A Yan-biao FU
%A Yu-lian WU
%J Journal of Zhejiang University SCIENCE B
%V 11
%N 1
%P 22-26
%@ 1673-1581
%D 2010
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B0900166

T1 - Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern
A1 - Qiu-ping XIE
A1 - Shun-liang GAO
A1 - Yan-biao FU
A1 - Yu-lian WU
J0 - Journal of Zhejiang University Science B
VL - 11
IS - 1
SP - 22
EP - 26
%@ 1673-1581
Y1 - 2010
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B0900166

somatostatinoma is a very rare neuroendocrine tumor that originates from D cells and accounts for less than 1% of all gastrointestinal endocrine tumors. The duodenum is the most frequent site for this tumor, followed by the pancreas. We here describe a 46-year-old Chinese woman who developed pancreatic somatostatinoma presenting with the characteristic “inhibitory” syndrome, but the symptoms were obscure and seemingly uncorrelated. This case is also unique for its large tumor size and mixed pathological pattern. Distal pancreatectomy was performed, and the patient has remained well since operation. As the syndromes of somatostatinoma may be obscure and atypical, clinicians should review all clinical findings to obtain an accurate diagnosis. Aggressive surgery is preferred to improve the survival.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1] Anene, C., Thompson, J.S., Saigh, J., Badakhsh, S., Ecklund, R.E., 1995. Somatostatinoma: atypical presentation of a rare pancreatic tumor. Am. J. Gastroenterol., 90(5):819-821.

[2] Barahona-Garrido, J., Aguirre-Gutierrez, R., Gutierrez-Manjarrez, J.I., Tellez-Avila, F.I., Lopez-Arce, G., Fomperoza-Torres, A., Criales, S., Sanchez-Cortes, E., Sarti, H.M., Yamamoto-Furusho, J.K., 2009. Association of GIST and somatostatinoma in a patient with type-1 neurofibromatosis: is there a common pathway? Am. J. Gastroenterol., 104(3):797-799.

[3] Cao, X.P., Liu, Y.Y., Xiao, H.P., Li, Y.B., Wang, L.T., Xiao, P., 2009. Pancreatic somatostatinoma characterized by extreme hypoglycemia. Chin. Med. J. (Engl.), 122(14):1709-1712.

[4] House, M.G., Yeo, C.J., Schulick, R.D., 2002. Periampullary pancreatic somatostatinoma. Ann. Surg. Oncol., 9(9):869-874.

[5] Janson, E.T., 2005. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J. Endocrinol. Invest., 28(11 Suppl. International):137-140.

[6] Klöppel, G., Perren, A., Heitz, P.U., 2004. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. N. Y. Acad. Sci., 1014(1):13-27.

[7] Konomi, K., Chijiiwa, K., Katsuta, T., Yamaguchi, K., 1990. Pancreatic somatostatinoma: a case report and review of the literature. J. Surg. Oncol., 43(4):259-265.

[8] Larsson, L.I., Hirsch, M.A., Holst, J.J., Ingemansson, S., Kuhl, C., Jensen, S.L., Lundqvist, G., Rehfeld, J.F., Schwartz, T.W., 1977. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet, 309(8013):666-668.

[9] Levy-Bohbot, N., Merle, C., Goudet, P., Delemer, B., Calender, A., Jolly, D., Thiefin, G., Cadiot, G., 2004. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol., 28(11):1075-1081.

[10] Maki, M., Kaneko, Y., Ohta, Y., Nakamura, T., Machinami, R., Kurokawa, K., 1995. Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern. Med., 34(7):661-665.

[11] Marakis, G., Ballas, K., Rafailidis, S., Alatsakis, M., Patsiaoura, K., Sakadamis, A., 2005. Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis: a case report. Pancreatology, 5(2-3):295-299.

[12] Moayedoddin, B., Booya, F., Wermers, R.A., Lloyd, R.V., Rubin, J., Thompson, G.B., Fatourechi, V., 2006. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr. Pract., 12(4):394-400.

[13] Mozell, E., Stenzel, P., Woltering, E.A., Rosch, J., O'Dorisio, T.M., 1990. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr. Probl. Surg., 27(6):309-386.

[14] Nesi, G., Marcucci, T., Rubio, C.A., Brandi, M.L., Tonelli, F., 2008. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J. Gastroenterol. Hepatol., 23(4):521-526.

[15] Sakazaki, S., Umeyama, K., Nakagawa, H., Hashimoto, H., Kamino, K., Mitsuhashi, T., Yamaguchi, K., 1983. Pancreatic somatostatinoma. Am. J. Surg., 146(5):674-679.

[16] Sato, T., Konishi, K., Kimura, H., Maeda, K., Yabushita, K., Tsuji, M., Demachi, H., Miwa, A., 2000. Strategy for pancreatic endocrine tumors. Hepatogastroenterology, 47(32):537-539.

[17] Soga, J., Yakuwa, Y., 1999. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J. Exp. Clin. Cancer Res., 18(1):13-22.

[18] Stelow, E.B., Woon, C., Pambuccian, S.E., Thrall, M., Stanley, M.W., Lai, R., Mallery, S., Gulbahce, H.E., 2005. Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. Diagn. Cytopathol., 33(2):100-105.

[19] Suzuki, H., Kuwano, H., Masuda, N., Hashimoto, S., Kanoh, K., Nomoto, K., Shimura, T., Katoh, H., 2008. Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepatogastroenterology, 55(85):1242-1245.

[20] Tjon, A.T.R.T., Jansen, J.B., Falke, T.H., Lamers, C.B., 1994. Imaging features of somatostatinoma: MR, CT, US, and angiography. J. Comput. Assist. Tomogr., 18(3):427-431.

[21] Tomono, H., Kitamura, H., Iwase, M., Kuze, S., Toyoda, F., Mori, N., Tamoto, E., Inuzuka, K., Fujita, H., Konishi, Y., Naito, M., Tanioka, F., 2003. A small, incidentally detected pancreatic somatostatinoma: report of a case. Surg. Today, 33(1):62-65.

[22] Vinik, A.I., Strodel, W.E., Eckhauser, F.E., Moattari, A.R., Lloyd, R., 1987. Somatostatinomas, ppomas, neurotensinomas. Semin. Oncol., 14(3):263-281.

[23] Zhang, Z.Y., Zhang, R., Wang, L., Shen, C., Yan, J.Q., Chen, Y.J., Li, Q.Y., Yang, W.P., Peng, C.H., Li, H.W., Zhou, G.W., 2008. Diagnosis and treatment of pancreatic somatostatinoma: a case report. Chin. Med. J. (Engl.), 121(22):2363-2365.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE